These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35693059)

  • 1. Recent breakthroughs in the treatment of chronic hepatitis Delta.
    Brancaccio G; Gaeta L; Vitale A; Gaeta GB
    Infez Med; 2022; 30(2):204-210. PubMed ID: 35693059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection
    Beilstein F; Blanchet M; Vaillant A; Sureau C
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.
    Wang W; Lempp FA; Schlund F; Walter L; Decker CC; Zhang Z; Ni Y; Urban S
    J Hepatol; 2021 Aug; 75(2):311-323. PubMed ID: 33845061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Future Management of Chronic Hepatitis D.
    Farci P; Anna Niro G
    Gastroenterol Hepatol (N Y); 2018 Jun; 14(6):342-351. PubMed ID: 30166948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
    Deterding K; Wedemeyer H
    AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Delta hepatitis: Epidemiology, diagnostic, natural history and treatment].
    Loureiro D; Castelnau C; Bed CM; Asselah T
    Rev Med Interne; 2022 Mar; 43(3):160-169. PubMed ID: 34799189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapies for hepatitis delta virus infection.
    Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
    Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bulevirtide for HBV and HDV infections.
    Yardeni D; Koh C
    Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges.
    Sagnelli C; Sagnelli E; Russo A; Pisaturo M; Occhiello L; Coppola N
    Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33671730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
    Asselah T
    J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
    Lampertico P; Roulot D; Wedemeyer H
    J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity
    Michelet M; Alfaiate D; Chardès B; Pons C; Faure-Dupuy S; Engleitner T; Farhat R; Riedl T; Legrand AF; Rad R; Rivoire M; Zoulim F; Heikenwälder M; Salvetti A; Durantel D; Lucifora J
    JHEP Rep; 2022 Mar; 4(3):100415. PubMed ID: 35141510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Urban S; Neumann-Haefelin C; Lampertico P
    Gut; 2021 Sep; 70(9):1782-1794. PubMed ID: 34103404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022.
    Lampertico P; Degasperi E; Sandmann L; Wedemeyer H;
    JHEP Rep; 2023 Sep; 5(9):100818. PubMed ID: 37593170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
    Nkongolo S; Hollnberger J; Urban S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.
    Zi J; Gao X; Du J; Xu H; Niu J; Chi X
    Front Microbiol; 2022; 13():838382. PubMed ID: 35464929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
    Nemteanu R; Clim A; Hincu CE; Gheorghe L; Ciortescu I; Plesa A
    Curr Issues Mol Biol; 2023 Sep; 45(10):7878-7890. PubMed ID: 37886941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and clinical aspects of hepatitis D virus infections.
    Dastgerdi ES; Herbers U; Tacke F
    World J Virol; 2012 Jun; 1(3):71-8. PubMed ID: 24175212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis delta virus: From infection to new therapeutic strategies.
    Niro GA; Ferro A; Cicerchia F; Brascugli I; Durazzo M
    World J Gastroenterol; 2021 Jun; 27(24):3530-3542. PubMed ID: 34239267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.